

Curriculum Vitae

1. Identification

Name: José António Pereira Delgado Alves

Nationality: Portuguese

E-mail: jose.alves@nms.unl.pt

2. Academic background

- Degree in Medicine em 1989, Faculty of Medical Sciences of Lisbon. Final classification 17 (0-20).
- Specialist in Internal Medicine since 1998.
- Specialist in Clinical Pharmacology since 2017.
- PhD in Medicine (Rheumatology) by University College of London: “Oxidative stress and Vascular Disease in Systemic Lupus Erythematosus and Antiphospholipid Syndrome”, in 2004.

3. Previous clinical positions

- Resident in Internal Medicine, Curry Cabral Hospital, Lisbon, Portugal, 1992 till 1998.
- Clinical Research Fellow: Lupus Arthritis Research Unit, St. Thomas' Hospital, London, 1994.
- Consultant in Internal Medicine, Curry Cabral Hospital, Lisbon, 1998 till 2009.
- Director of Internal Medicine Department, Fernando da Fonseca Hospital, Amadora, Portugal, from 2009 till the present.
- Director of the Systemic Immunomediated Diseases Unit Fernando da Fonseca Hospital, Amadora, from 2011 till the present.

4. Academic activity

- PhD student, Centre for Rheumatology, Department of Medicine, *University College London*, 1999 to 2002.

- Honorary Lecturer, Department of Medicine, *University College of London*, 2002 till 2004.
- Senior Lecturer in Human Physiopathology, Department of Pharmaceutical Sciences, Lusófona University, Lisbon, 2003.
- Senior lecturer in Pharmacology, Faculty of Medical Sciences, Lisbon, 2003 to 2005.
- Auxiliary Professor of Pharmacology: Faculty of Medical Sciences, Lisbon, 2005 till 2014.
- Associate Professor of Medicine: Faculty of Medical Sciences, Lisbon, from 2014 till the present.
- Director of the Department of Post-graduate Education, Curry Cabral Hospital, Lisbon, 2003 to 2009.
- Director of the Department of Post-graduate Education and Clinical Research, Fernando Fonseca Hospital, Amadora, from January 2015 till April 2018.

5. Scientific Activity

5.1 Positions and coordination activities

- Principal Investigator and Coordinator of the “Immune response and Vascular Disease Research Group” of CEDOC (Centre for Chronic Diseases)/ NOVA Medical School since 2013.
- Supervision of 6 PhD students in the area of vascular disease and clinical immunology.
- Director of the Clinical Research Department of CEDOC of NOVA Medical School, Lisbon, from 2011 till 2013.
- Member of the Scientific Council the Faculty of Medical Sciences, Lisbon, since 2014 till 2020.
- Member of the Faculty of the PhD program of the Faculty of Medical Sciences, Lisbon, since 2014 till the present.
- Member of the scientific Committee os the Autoimmune Diseases Study Group of Portuguese Society of Internal Medicine, from 2016 till the present date.
- President of the Autoimmune Diseases Study Group of the Portuguese Society of Internal Medicine, from 2012 to 2016 and from 2022 to the present.
- Scientific advisor for the Portuguese Health Administration Agency (DGS) on Internal Medicine since 2009.

- Scientific advisor for INFARMED (Portuguese Drug Agency) for biologic therapy in autoimmune diseases since 2014.
- Member of the Expert Committee of ECRIN (European Clinical Research Infrastructure Network) since 2019.
- Chairman of the Expert Committee of ECRIN since 2020.
- Member of the EBIM (EFIM) committee since 2022.

5.2 Other research activities, grants and awards

Clinical Trials

Principal Investigator in more than 10 phase 1, 2 and 3 multicentre clinical trials in the areas of rheumatology, vascular medicine and thrombosis.

Main interventional trials as a principal investigator:

Phase I

- 1) BI trial N° 1199-0340. A Phase I trial to investigate the effect of Nintedanib pharmacokinetics of a combination of ethinylestradiol and levonorgestrel in female patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).

Phase II

- 1) B7931028: A phase 2b multicenter dose ranging study to evaluate efficacy and safety of PF-06700841 in systemic lupus erythematosus.
- 2) STEADY: ALX0061-C204 “A Phase II Multi-center, Randomized, Double-Blind, Placebo-Controlled, Dose-Range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Systemic Lupus Erythematosus Subjects with Moderate to Severe Active Disease”
- 3) LUPIL-2 “A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of ILT-101 in patients with active moderate to severe systemic lupus erythematosus (SLE) (Lupil-2) (National Coordinator)”
- 4) BIOSEQUETIA: “Efficacy, pharmacokinetics, and safety of BI695500 versus rituximab in patients with moderately to severely active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial”

Phase III

- 1) Bliss-SC: HGS1006-C1115 “A phase 3, multi-center, randomized, double-blind, placebo-controlled, 52 week study to evaluate the efficacy and safety of

- belimumab (HGS1006) administered subcutaneously to subjects with systemic lupus erythematosus”
- 2) To-Space: ML28709 “A phase IIIb study to evaluate the efficacy, safety and tolerability of subcutaneous tocilizumab given as monotherapy or in combination with methotrexate or other non-biologics DMARDs in subjects with rheumatoid arthritis”
 - 3) SENSCIS: 1199.214 “A double blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib, 150 mg twice daily for 52 weeks (primary endpoint timepoint) to 100 weeks in patients with ‘Systemic Sclerosis associated interstitial lung disease (SSc-ILD)’”
 - 4) FOCUSSED: WA29767 “A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis”
 - 5) ATMOSPHERE: CSPP100F2301 “A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II-IV)”

Research Grants

- Portuguese Foundation for Science and Technology: 1999 - 2002 (PhD).
- Wyeth International, USA, 2007: “Recombinant human soluble TNF α receptor in cachetic tumor bearing rats”. 2007 -2009.
- AstraZeneca Foundation: “Anti-HDL antibodies, paraoxonase and oxidative stress: assessment of vascular risk”. 2008-2010.
- Portuguese Foundation for Science and Technology: "Lupus and its compensation in unaffected relatives by T-cell regulation". 2007-2010.
- Research Grant in Autoimmunity, Portuguese Society of Internal Medicine: “NOTCH system and angiogenesis in systemic sclerosis. 2013-2014.
- Portuguese Foundation for Science and Technology, FCT Research Grant: “Anti-ApoA-I antibodies in Alzheimer’s disease”. 2013-2014.
- Portuguese Foundation for Science and Technology (INova4Health): “Atherogenesis and antiApoA-I and anti-paraoxonase antibodies in Systemic lupus”: 2015-2017.
- Research Grant in Autoimmunity, Portuguese Society of Internal Medicine: “Vascular memory in endothelium dysfunction associated systemic conditions”. 2016-2017.
- Portuguese Foundation for Science and Technology (INova4Health): “HDL regulation of T Cell response in Systemic Lupus”: 2016-2017.

- 2018 – NEDM/Lilly Scholarship, Diabetes Mellitus Studies Nucleus (NEDM), Portuguese Society of Internal Medicine (SPMI) (2018-2020)
- 2018 –Helena Saldanha (Boehringer Ingelheim) Scholarship, Diabetes Mellitus Studies Nucleus (NEDM), Portuguese Society of Internal Medicine (SPMI) (2018-2020)

Awards

- Clinical Research in Autoimmunity Award, Portuguese Society of Internal Medicine, 2006.
- Clinical Research in Autoimmunity Award, Portuguese Society of Internal Medicine, 2010.
- 2015 - Pfizer Award Best Poster Autoimmunity, Autoimmune Diseases Studies Nucleus (NEDAI), Portuguese Society of Internal Medicine (SPMI).
- Clinical Research in Autoimmunity Award, Portuguese Society of Internal Medicine, 2018.
- 2018 – Maratona da Saúde, RTP/FCT
- 2019 – NOVARTIS | Excellence in Fundamental Medical Research, NOVA Medical School.

6. Publications

Articles:

- Marta C Amaral , F Seguro Paula , Joana Caetano , Paul RJ Ames, J Delgado Alves. Re-evaluation of nailfold capillaroscopy in discriminating primary from secondary Raynaud's phenomenon and in predicting systemic sclerosis: a randomised observational prospective cohort study. *Expert Review of Clinical Immunology.* 2024, in press. Doi: 10.1080/1744666X.2024.2313642
- Marinho A, Delgado Alves J, Fortuna J, Faria R, Almeida I, Alves G, Araujo Correia J, Campar A, Brandão M, Crespo J, Marado D, Matos-Costa J, Oliveira S, Salvador F, Santos L, Silva F, Fernandes M and Vasconcelos C. Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance. *Front. Immunol.* 2023 14:1117699. doi: 10.3389/fimmu.2023.1117699.
- Rodrigues LM, Caetano J, Andrade SF, Rocha C, Alves JD, Ferreira HA. Studying Erythromelalgia Using Doppler Flowmetry Perfusion Signals and Wavelet Analysis-An Exploratory Study. *Biomedicines.* 2023 Dec 16;11(12):3327. doi: 10.3390/biomedicines11123327.
- Barosa M, Barroso T, Marques R, Caetano J, Alves JD. Clinically significant contrast-associated acute kidney injury after emergent computed tomography angiography of the cerebral arteries. *Eur J Intern Med.* 2023 Sep;115:146-148. doi: 10.1016/j.ejim.2023.06.004.
- Araújo Correia J, Crespo J, Alves G, Salvador F, Matos-Costa J, Alves JD, Fortuna J, Almeida I, Campar A, Brandão M, Faria R, Marado D, Oliveira S, Santos L, Silva F, Vasconcelos C, Fernandes M, Marinho A. Biologic therapy in large and small vessels vasculitis, and Behcet's disease: Evidence- and practice-based guidance. *Autoimmun Rev.* 2023 Aug;22(8):103362. doi: 10.1016/j.autrev.2023.103362.
- Mafalda F. Teixeira , Mónica Lopes, Frederico Batista, Ana Bastos Furtado, José Delgado Alves. Retrospective Evaluation of Morbimortality and 6-month Survival Rate of \geq 75-year-old Patients Treated with Non-invasive Mechanical Ventilation in an Intermediate Care Unit. *Cureus* 2022: doi:10.7759/cureus.

- Oliveira R, Ribeiro R, Melo L, Grima B, Oliveira S, Alves JD, Connective tissue disease-associated interstitial lung disease, Pulmonol 2022. Volume 28, Issue 2, Pages 113-118. doi.org/10.1016/j.pulmoe.2020.01.004.
- Trindade, Miguel; Carvalho, Joana; Barosa, Mariana; Serôdio, João; Oliveira, Ricardo; Furtado, Ana; Favas, Catarina; Alves, José. "Wilson's Disease - first report of two combined mutational variants in a Portuguese patient". EJCRIM 2022; 9: doi:10.12890/2022_003141.
- Fernandes das Neves, Marisa; Jury, Elizabeth; Delgado Alves, José. HDL influences CD4 T cell proliferation in SLE and increases TGF- β 1 expression: a potential role in the protection from atherosclerosis and autoimmunity. Lupus 2021 Oct;30(12):2019-2021. doi: 10.1177/09612033211034557.
- Joana Azevedo Carvalho, Leonor Boavida, Isabel Amorim Ferreira, Bruno Grima, José Delgado Alves. Native valve Aspergillus endocarditis in a non-neutropenic immunocompromised patient treated with anti-TNF α blockers. Cureus 2021. doi: 10.7759/cureus.
- Fernandes Serodio, J., Trindade, M., Achega, M., Faria, D., Maurício, J., Batista, F., Favas, C. e Delgado Alves, J. 2021. Etiologia, Tratamento e Prognóstico da Pericardite Aguda. *Medicina Interna* 2021; 27, 1: 22–27. doi.org/10.24950/O/185/19/1/2020.
- Seguro Paula F, Delgado Alves J. The role of the Notch pathway in the pathogenesis of systemic sclerosis: clinical implications. Expert Rev Clin Immunol. 2021 Dec;17(12):1257-1267. doi: 10.1080/1744666X.2021.2000391.
- Caetano, J., Batista, F., Amaral, M.C. et al. Acute hospitalization in a cohort of patients with systemic sclerosis: a 10-year retrospective cohort study. Rheumatol Int, 2021. doi.org/10.1007/s00296-021-04983-4.
- Marta Alenquer, Tiago Milheiro Silva, Onome Akpogheneta et al. Saliva molecular testing bypassing RNA extraction is suitable for monitoring 2 and diagnosing SARS-CoV-2 infection in children. MedRxiv 2021; DOI: 10.1101/2021.08.11.21261899.

- Marisa Neves, Joana Batuca, J Delgado Alves. The role of high-density lipoprotein in the regulation of the immune response: implications for atherosclerosis and autoimmunity. *Immunology*. 2021; 164:231–241.
- Boavida L, Carvalho J, Oliveira S, et al. Muscle Infarction Following Rapid Glycemic Control in a Patient With Diabetes Associated Microvascular Disease. *Cureus* 2021; 13(8): e17182. DOI 10.7759/cureus.17182
- Rune Matthiesen, Chris Lauber, Julio L Sampaio et al. Shotgun mass spectrometry-based lipid profiling identifies and distinguishes between chronic inflammatory diseases. *EBioMedicine*. 2021 Jul 23;70:103504. doi: 10.1016/j.ebiom.2021.103504.
- Serodio JF, Lopes M, Ribeiro R, Trindade M, Favas C, Alves JD. Hepatic fascioliasis as an important differential diagnosis to cholangiocarcinoma. *J Travel Med*. 2021 Apr 14:taab061. doi: 10.1093/jtm/taab061.
- Ribeiro R, Serôdio J F, Amaral M C, et al. Sensorineural Hearing Loss and Systemic Autoimmune Disease: The Experience of a Systemic Immune-Mediated Diseases Unit. *Cureus* 2021, 13(3): e14075. DOI 10.7759/cureus.14075.
- Gonçalves J, Sousa RL, Jacinto MJ et al. Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures. *Front Med (Lausanne)*. 2020 Dec 18;7:603996. doi: 10.3389/fmed.2020.603996.
- Faria DC, Ribeiro R, Sousa-Uva M, Freitas A et al. Unusual submitral aneurisms. *Circ Cardiovasc Imaging*. 2020 Oct;13(10): e010466. doi: 10.1161/CIRCIMAGING.120.010466. Epub 2020 Sep 22.
- Maria Joao Paiva Lopes, Joana R. Batuca, Sofia Gouveia, Marta Alves, Ana Luisa Papoila, José Delgado Alves. Antibodies towards high-density lipoprotein components in patients with psoriasis. *Arch Dermatol Res*. 2020 Mar; 312(2):93-102.
- Caetano J, Paula FS, Amaral M, Oliveira S, Alves JD. Nailfold Videocapillaroscopy Changes Are Associated With the Presence and Severity of Systemic Sclerosis-Related Interstitial Lung Disease. *J Clin Rheumatol*. 2019 Apr;25(3): e12-e15.
- Oliveira R, Teixeira M, Cochito S, Furtado A, Grima B, Alves J, Drug-Induced Aseptic Meningitis Following Spinal Anesthesia, European Journal of Case Reports in Internal Medicine, 2 (2019); doi.org/10.12890/2019_001334.

- Ribeiro R, Batista F, Seguro Paula F, Delgado Alves J. Changes in Iron Metabolism Induced by Anti-Interleukin-6 Receptor Monoclonal Antibody are Associated with an Increased Risk of Infection. *Pharmaceuticals (Basel)*. 2019 Jun 28; 12(3).
- Frias M, Pagano S, Delgado Alves J, Batuca J, Virzi J, Satta N, Vuilleumier N. ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1. *J Immunol Methods*. 2019 Jun; 469:33-41.
- Paul RJ Ames, Mira Merashli, Tommaso Bucci, Fabrizio Gentile, José Delgado Alves. Antiphospholipid Antibodies and Renal Transplant: a Systematic Review and Meta-analysis, *Semin Arthritis Rheum*. 2018 Oct 19. pii: S0049-0172(18)30591-2.
- Joana R. Batuca, Marta C. Amaral, Catarina Favas, Gonçalo C Justino, Ana L Papoila, Paul RJ Ames, José Delgado Alves. Antibodies against HDL Components in Ischaemic Stroke and Coronary Artery Disease. *Thromb Haemost*. 2018; Jun;118(6):1088-1100.
- Paul Ames, Tommaso Bucci, Mira Merashli, Marta Amaral, Alessia Arcaro, Fabrizio Gentile, Jaffar Nourooz-Zadeh, José Delgado Alves. Oxidative/nitrative stress in the pathogenesis of systemic sclerosis: are antioxidants beneficial? *Free Radical Research*, 2018. (DOI: 10.1080/10715762.2018).
- Goncalves J, Santos M, Acurcio R et al. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. *Aliment Pharmacol Ther*. 2018 Sep;48(5):507-522.
- Merashli M, Delgado Alves J, Ames PRJ. Clinical relevance of antiphospholipid antibodies in systemic sclerosis: a systematic review & meta-analysis. *Sem Arthritis Rheum* 2017; 46: 615-624.
- Batuca JR, Amaral MC, Favas C, Paula FS, Ames PRJ, Papoila AL, Delgado Alves J. Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial. *Br J Clin Pharmacol*. 2017 May;83(5):1002-1010.
- Paiva-Lopes MJ, Delgado Alves J. Psoriasis-associated vascular disease: the role of HDL. *J Biomed Sci*. 2017 Sep 14;24(1):73. doi: 10.1186/s12929-017-0382-4.
- Ames PRJ, Delgado Alves J, Gentile F. Coagulation and complement in antiphospholipid syndrome. *Thrombosis Research* 2017, 158: 149–151.

- Merashli M, Alves JD, Gentile F, Ames PRJ. Relevance of antiphospholipid antibodies in multiple sclerosis: A systematic review and meta-analysis. *Semin Arthritis Rheum.* 2017 Jun; 46(6): 810-818.
- Peres, João; Martins, Rita; Alves, José Delgado; Valverde, Ana. Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost–utility analysis. *Porto Biomedical Journal.* 2017, 2(3):81-85.
- O Amengual, R Forastiero, M Sugiura-Ogasawara et al. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. *Lupus.* 2017 Mar; 26(3):266-276.
- Paula FS, Ferreira I, Amaral MC, Delgado Alves J. Systemic sclerosis-like nailfold videocapillaroscopy changes in genetic myopathies. *Rheumatology (Oxford).* 2016 Oct; 55(10):1911-2.
- Liliana Cunha, Gisela Marcelino, Marta C Amaral, J Delgado Alves. Magnesium – association with inflammation and renal disease in Systemic Lupus Erythematosus. *Port J Nephrol Hypert* 2015; 29(4): 323-331.
- Caetano J, Delgado Alves J. Heart rate and cardiovascular protection. *Eur J Intern Med.* 2015; Feb (15): 44-8.
- Tiago Brito, Clara Portugal, Luísa Sancho, Carina Carvalho, Bruno Grima, José Delgado Alves. Sensibilidade das Enterobacteriáceas Produtoras de Beta-Lactamases de Espectro Alargado à Fosfamicina. *Medicina Interna,* 2015; 22 (3): 131-5.
- M. Neves, M Amaral, S Oliveira, J Delgado Alves. Treatment of Systemic Sclerosis with Tocilizumab. *Rheumatology (Oxford).* 2015; 54 (2):371-2.
- Caetano J, Pereira F, Oliveira S, Delgado Alves J. IgA-dominant postinfectious glomerulonephritis induced by methicillin-sensitive *Staphylococcus aureus*. *BMJ Case Reports* 2015; doi:10.1136/bcr-2014-208513.
- Sokoll, K. B., Batuca, J., Lopez, L. R., Hensor, E., Emery, P., Delgado Alves, J., & Ames, P. R. J. (2014). Effects of Atorvastatin on Atherosclerosis and Atherogenesis in Systemic Lupus Erythematosus: A Pilot Study. *ISRN Immunology.*

- Fernandes das Neves M, Caetano J, Oliveira S, Delgado Alves J. Immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle treated with a combination of rituximab and cyclophosphamide. *BMJ Case Rep.* 2015 Aug 3; 2015. pii: bcr2014206250. doi: 10.1136/bcr-2014-206250.
- Caetano J, Fernandes das Neves M, Oliveira S, Delgado Alves J. Xanthogranulomatous pyelonephritis presenting as palmoplantar keratoderma. *BMJ Case Rep.* 2014; doi:10.1136/bcr-2014-208511.
- Paula FS, Alves JD. Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. *Biologics.* 2014; 8:1-12.
- Luis Brito-Avô, José Delgado Alves, João Matos Costa, Ana Valverde, Lélita Santos, Francisco Araújo, Patrício Aguiar, António Marinho, Anabela Oliveira, Daniel Gomes. Recomendações para o Diagnóstico da Forma Tardia da Doença de Pompe. *Acta Med ort*, 2014; 27 (4): 525-29.
- Caetano J, Fernandes das Neves M, Oliveira S, Delgado Alves J. Refractory Wegener's granulomatosis presenting with alveolar haemorrhage, treated with rituximab. *BMJ Case Rep.* 2014; doi:10.1136/bcr-2014-208510.
- Sara Machado, Nuno Inácio, Filipe Paula et al. Seronegative Wegener's granulomatosis presenting as a multiple cranial neuropathy. *J Neurol Disord* 2014; 2: 149. doi:10.4172/2329-6895.1000149.
- Andréa Marques, António Mota, Helena Canhão et al. A FRAX model for the estimation of osteoporotic fracture probability in Portugal. *Acta Reumatol Port* 2013; 38: 104-12.
- Delgado Alves J, Marinho A, Serra MJ. Tocilizumab: is there life beyond anti-TNF blockade? *Int J Clin Prac* 2011; 65: 508-13.
- Neves M, Delgado Alves J. Factors implicated in the generation and persistence of long-lived plasma cell-mediated autoimmunity. *Autoimmunity Rev*, 2011; 10: 375-382.
- Ames PR, Batuca JR, Ciampa A, Iannaccone L, Alves JD. Clinical Relevance of Nitric Oxide Metabolites and Nitritative Stress in Thrombotic Primary Antiphospholipid Syndrome. *J Rheumatol.* 2010; 37: 2523-30.

- Ames PR, Margaglione M, Mackie S, Alves JD. Eosinophilia and Thrombophilia in Churg Strauss Syndrome: A Clinical and Pathogenetic Overview. *Clin Appl Thromb Hemost.* 2010; 16(6):628-36.
- PRJ Ames E Matsuura, J Batuca, A Ciampa, LL Lopez, F Ferrara, I Iannaccone, J Delgado Alves. High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. *Lupus*, 2010; 19(6):711-6.
- Amaral MC, Favas C, Alves JD, Riso N, Riscado MV. Stress-related mucosal disease: incidence of bleeding and the role of omeprazole in its prophylaxis. *Eur J Intern Med.* 2010; 21(5):386-8.
- Amaral MC, Favas C, Alves JD. Persistency of low levels of anticardiolipin and anti-Beta2 Glycoprotein1 in thrombosis. *Eur J Inter Med* 2010; 21:101-103.
- SA Pereira, JR Batuca, U Caixas, T Branco, J Delgado Alves, I Germano, F Lampreia, EC Monteiro. Effect of Efavirenz on High-Density Lipoprotein anti-oxidant properties in HIV-infected patients. *Br J Clin Pharmacology* 2009, 68: 891-897.
- Ames PR, Margaglione M, Mackie S, Alves JD. Eosinophilia and Thrombophilia in Churg Strauss Syndrome: A Clinical and Pathogenetic Overview. *Clin Appl Thromb Hemost.* 2009, Oct 14. [Epub ahead of print]
- M Charakida, C Besler, JR Batuca, S Sangle, S Marques, M Sousa, G Wang, D Tousoulis, J Delgado Alves, C Mackworth-Young, G Hughes, D D'Cruz, T Luscher, U Landmesser. Vascular Dysfunction in Primary Phospholipid Syndrome: Role of Dysfunctional High Density Lipoprotein. *JAMA* 2009; 302: 1210-17.
- Amaral MC, Delgado Alves J. Pathogenesis of Multi-Organic Failure in Autoimmune Diseases. *Autoimmun Rev* 2009; 8: 525-8.
- Batuca JR, Delgado Alves J. C-Reactive Protein in Systemic Lupus Erythematosus. *Autoimmunity* 2009; 42(4): 1-4.
- Ames PR, Margarita A, Alves JD. Antiphospholipid Antibodies and Atherosclerosis: Insights from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome. *Clin Rev Allergy Immunol.* 2009; 37: 29-35.
- Batuca JR, Ames PRJ, Amaral M, Favas C, Isenberg DA, Delgado Alves J. Anti-atherogenic and anti-inflammatory properties of high density lipoprotein are

affected by specific antibodies in patients with systemic lupus erythematosus. *Rheumatology* 2009 Jan; 48(1):26-31.

- Ames PRJ, Antinolfi I, Ciampa A, Batuca J, Scenna G, Lopez LR, Delgado Alves J, Iannaccone L, E Matsuura. Primary Antiphospholipid Syndrome. A Low Grade Auto-Inflammatory Disease? *Rheumatology (Oxford)*. 2008 Dec; 47(12):1832-7.
- J Delgado Alves, E Steinhagen-Thiessen, R Darioli, U. Hostalek, A. Vogt. Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk. *Curr Med Res Opin* 2008; 24: 2815-20.
- MR Ehrenstein, JD Alves. Antibodies and other biomarkers – pathological consequences. *Lupus* 2008 17: 256-58.
- Batuca JR, Ames PRJ, Isenberg DA, Delgado Alves J. Antibodies towards high density lipoproteins components inhibit paraoxonase activity in patients with systemic lupus erythematosus. *Ann NY Acad Sciences*, 2007; 11108: 137-46.
- Margarita A, Batuca J, Scenna G, Delgado Alves J, Lopez L, Iannaccone L, Matsuura E, Ames PRJ. Subclinical Atherosclerosis in Primary Antiphospholipid Syndrome *Ann NY Acad Sciences*.2007 1108 (1), 475–480.
- Ames PRJ, Delgado Alves J, Lopez LR, Gentile F, Margarita A, Batuca J, Scenna G, Brancaccio V, Matsuura E. Antibodies against b2-glycoprotein I complexed with an oxidised lipoprotein relate to intima media thickening of carotid arteries in primary antiphospholipid syndrome. *Clin Dev Immunol*. 2006; 13: 1-9.
- Delgado Alves J, Clapp BR, Stidwill R, Chen PP, Hingorani A D, Singer M, Isenberg DA. Human Monoclonal IgG Anticardiolipin Antibodies Induce Nitric Oxide Synthase Expression. *Atherosclerosis*. 2006; 185: 246-53.
- Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P and the CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. *Circulation*. 2005; 112: 2426-35.
- Delgado Alves J, Mason LJ, Ames PRJ, Chen PP, Rauch J, Levine JS, Subang R, and Isenberg DA. Antiphospholipid Antibodies Are Associated With Enhanced Oxidative Stress, Decreased Plasma Nitric Oxide And Paraoxonase Activity In An Experimental Model. *Rheumatology (Oxford)*. 2005; 44: 1238-44.

- PRJ Ames, L Iannaccone, J Delgado Alves, A Margarita, LR Lopez, V Brancaccio. Factor XIII in primary antiphospholipid syndrome. *J Rheumatol* 2005; 32: 1058-62.
- Delgado Alves J, Radway-Bright EL, Lee S, Grima B, Hothersall J, Ravirajan CT, Isenberg DA. Antiphospholipid antibodies are induced by *in vitro* fertilization and correlate with paraoxonase activity and total antioxidant capacity of plasma in infertile women. *Lupus*, 2005; 14: 373-380.
- Luis Monteiro Rodrigues, Nuno Furtado, José Martins Magro, Francisco Rei, José Alves. Interesse Terapêutico da Vasodilatação Periférica Induzida por Prostaciclina no Tratamento duma Doente com Fenómeno de Raynaud Associado a Doenças Autoimunes. *Rev Lus Ciências e tecnologias de Saúde* 2005; 2:61-6.
- Luis Monteiro Rodrigues, Pedro Contreiras Pinto, José Martins Magro, Milene Fernandes, José Alves. Exploring the influence of skin perfusion on transepidermal water loss. *Skin Res Technol* 2004, 10: 257-62.
- The European Antiphospholipid Study Group. Features associated with epilepsy in the antiphospholipid syndrome. *J Rheumatology*, 2004; 31 (7): 1344-8.
- Delgado Alves J, Inanc M, Grima B, Soromenho F, Isenberg DA. Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome related thrombocytopenia. *EJIM* 2004; 15 (3): 162-7.
- The European Antiphospholipid Syndrome Study Group. Prevalence and clinical correlations of antibodies against six β 2-Glycoprotein-I – related peptides in the antiphospholipid syndrome. *J Clin Immunol*, 2003; 23(5): 377-83.
- Delgado Alves J, Grima B. Oxidative stress in Systemic Lupus Erythematosus and Antiphospholipid syndrome: a gateway to atherosclerosis. *Current Rheumatology Reports* 2003; 5(5): 383-390.
- Delgado Alves J, Ames PRJ. Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome. *Immunobiology* 2003; 207(1): 23-8.
- Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity between anti-cardiolipin, anti-high density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. *Rheumatology* 2003; 42(7): 893-9.

- Delgado Alves J, Ames PRJ, Donohue S, Nourooz-Zadeh J, Ravirajan C, Isenberg DA. Antibodies to high-density lipoprotein and β_2 -glycoprotein 1 are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid antibody syndrome. *Arthritis & Rheumatism* 2002; 46 (10): 2686-94.
- Ames PRJ, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibodies independently predict intima/media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. *Lupus* 2002; 11:208-214.
- Martin Martins J, Alves J, Trinca A, Grima B, do Vale S, Vasconcelos T, Riso N, Riscado V, Charneco da Costa J. Personality, brain asymmetry and neuroendocrine reactivity in two immune-mediated disorders: a preliminary report. *Brain, Behavior, and Immunity* 2002; 16: 383-97.
- Ames PRJ, Tommasino C, Alves J, Morrow JD, Iannaccone L, Fossati G, Caruso S, Caccavo F, Brancaccio V. Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. *Lupus*, 2000; 9: 1-8.
- Ames PRJ, Alves J, Pap AF, Ramos P, Khamashta MA, Hughes GRV. Fibrinogen in Systemic Lupus Erythematosus. More than an acute phase reactant? *J Rheumatology*, 2000; 27: 1190-5.
- Ames PRJ, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh. Oxidative stress in Systemic Lupus Erythematosus and allied disorders with vascular involvement. *Rheumatology* 1999; 38: 529-34.
- Alves J, Panarra A, Riscado M. Avaliação capilaroscópica peri-ungueal em patologia auto-imune: correlação clínico-morfológica. *Rev Port Medicina Interna* 1998; 5 (1): 16-22.
- Campos M, Alves J, Santos I, Riscado V, Cordeiro A. Estudo comparativo entre dois métodos de detecção de Anticoagulante lúpico – aPTT e DRVVT. *Bol Hospitais Civis* 1998; 52 (1): 39-43.
- Alves J, Falcão J, Martin Martins J, Saraiva MC, Godinho C, Arranhado E, Riso N, Charneco da Costa J. Immunoglobulin levels and autoantibody titers in women with hyperprolactinaemia. *Clin Exp Rheumatology* 1998, Jul-Aug; 16 (4): 515-6.
- Ames PR, Nourooz-Zadeh J, Tommasino C, Alves J, BrancaccioV, Anggard EE. Oxidative stress in Primary Antiphospholipid Syndrome. *Thrombosis & Haemostasis* 1998, Feb; 79 (2): 447-9.

- Ames PR, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L, Khamashta MA, Hughes GR, Brancaccio V. The coagulation / fibrinolysis balance in Systemic Sclerosis. Evidence for a haematological stress syndrome. *Br J Rheumatology* 1997; 36 (10): 1045-50.
- Alves J, Lúcio P, Frade MJ, Panarra A, Ventura A, Riscado M. Linfoma não Hodgkin e Doença de Hodgkin – complicaçāo ou associaçāo? *Rev Port Medicina Interna* 1997; 4 (4): 252-56.
- European Sjögren Syndrome Study Group. Assessment of the European Classification Criteria for Sjögren's Syndrome in a series of clinically defined cases: results of a prospective multicenter study. *Ann Rheum Dis* 1996; 55:116-21.
- Ruiz-Irastorza G, Lima F, Alves J, Khamashta MA, Simpson J, Hughes GR, Buchanan NM. Increased rate of Lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. *Br J Rheumatology* 1996, Feb; 35 (2): 133-8.

Books (chapters):

- João Serôdio, Catarina Favas, Susana Oliveira e José Delgado Alves. Giant-Cell Arteritis" in Giant-Cell Arteritis, ISBN 978-1-83969-209-3, by Ed. Imtiaz Chaudhry, Intech Open, London 2021, in press.
- J. Caetano, S. Oliveira, J. Delgado Alves. Biologic Therapy in Systemic Sclerosis in Systemic Sclerosis, Ed. Mislav Radić, Intech editors, Croatia, 2017.
- Isabel Ferreira, José Delgado Alves. Atherogenesis and vascular disease in SLE in Systemic Lupus Erythematosus, Ed Hani Almoallim, Intech editors, Croatia, 2012.
- JR Batuca, MC Amaral, J Delgado Alves. Humoral Mechanisms of Atherogenesis in Contemporary Challenges in Autoimmunity, Ed. Yehuda Shoenfeld and M. Eric Gershwin, Blackwell Publishing, Boston, 2009.
- José Delgado Alves. Oxidative stress and Vascular Disease in Systemic Lupus Erythematosus and Antiphospholipid Syndrome. PhD thesis. UCL Edition, London, 2004.

7. Participations in scientific meetings

More than 500 oral communications, 350 workshops and more than 300 conferences in national and international meetings.

8. Organization of Scientific Meetings

Member of the organizing and scientific committee of more than 100 national and international meetings in Portugal and abroad, including president of the Portuguese Congress of Internal Medicine and the Portuguese Congress of Autoimmunity.

9. Other interests

Acrobatic gymnastics for 15 years, with more than 150 internationalizations, representing Portugal. Books (reading and collecting), theatre, jazz music and old fashion rock & roll!

Lisbon, 20/04/2023

A handwritten signature in black ink, appearing to read "José Pedro de Almeida".